Announced Mon, 26 Oct, 2026 · 18:57 IST
Board to review September quarter results and consider fundraising
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction
Awaiting price reaction for this filing.
AI summary
Sudarshan Pharma's board meets on 29 October 2026 to approve unaudited standalone and consolidated results for the quarter and half-year ended 30 September 2026. It will also consider a proposal to raise funds through preferential issue, institutional placement, warrants, convertible securities or debt securities, subject to approvals. The trading window remains closed until 48 hours after results are declared.
Likely market impact
Results could shift earnings expectations and the share price. Any approved fundraising may add capital but could dilute existing shareholders.